CerebraCell

BioRestorative Therapies is a clinical-stage biotechnology company focused on developing regenerative medicine products using proprietary stem cell technologies. The company operates two primary platforms: the CerebraCell program, which targets neurological conditions such as ischemic stroke and traumatic brain injury, and the ThermoCell program, which addresses metabolic disorders like obesity and type 2 diabetes. Its lead clinical candidate, BRTX-100, is an autologous cell therapy currently in Phase 2 trials for the treatment of chronic lumbar disc disease. BioRestorative's approach leverages specialized cell processing, including the use of hypoxic cultured mesenchymal stem cells, to enhance therapeutic survival and efficacy in damaged tissues. The company aims to provide transformative treatments for significant unmet needs in orthopedics, neurology, and metabolic health.